AVN492

CAS No. 1220646-23-0

AVN492 ( —— )

Catalog No. M19954 CAS No. 1220646-23-0

AVN-492 is a potent and selective 5-HT6R Antagonist (Ki:?91 pM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 41 In Stock
5MG 67 In Stock
10MG 111 In Stock
25MG 224 In Stock
50MG 336 In Stock
100MG 483 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    AVN492
  • Note
    Research use only not for human use.
  • Brief Description
    AVN-492 is a potent and selective 5-HT6R Antagonist (Ki:?91 pM).
  • Description
    AVN-492 is a potent and selective 5-HT6R Antagonist (Ki:?91 pM).
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    5-HT Receptor
  • Recptor
    5-HT6;5-HT6R
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1220646-23-0
  • Formula Weight
    359.45
  • Molecular Formula
    C17H21N5O2S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 100 mg/mL
  • SMILES
    CNc1nn2c(C)c(N(C)C)c(C)nc2c1S(=O)(=O)c1ccccc1
  • Chemical Name
    N2N6N657-pentamethyl-3-(phenylsulfonyl)pyrazolo[15-a]pyrimidine-26-diamine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Ivachtchenko AV et al. AVN-492 A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation. J Alzheimers Dis. 2017;58(4):1043-1063.
molnova catalog
related products
  • Serotonin hydrochlor...

    Serotonin hydrochloride is a monoamine neurotransmitter and Endogenous 5-HT receptor agonist.

  • Pizotifen Malate

    Pizotifen malate is a highly selective 5-HT receptor blocking agent, which is a benzocycloheptane based drug.

  • Cannabigerol

    Cannabigerol is a high affinity α±2-adrenergic receptor agonist, moderate affinity 5-HT1A receptor antagonist, and low affinity CB1 receptor antagonist ; also binds to the CB2 receptor; it can relieve interocular pressure, which may be of benefit in the treatment of glaucoma.